基因编辑在非酒精性脂肪性肝病动物模型构建中的应用及研究进展

doi:10.3969/j.issn.1000-8535.2023.03.002

广州医药 ›› 2023, Vol. 54 ›› Issue (3): 8-13.DOI: 10.3969/j.issn.1000-8535.2023.03.002

基因编辑在非酒精性脂肪性肝病动物模型构建中的应用及研究进展

李兴会^1,2, 郭晨^1,2, 陈汉清^1,2

1 广州市第一人民医院医学研究与创新转化中心(广州 510180)
2 华南理工大学附属第二医院消化内科(广州 510180)

收稿日期:2022-12-10 出版日期:2023-03-20 发布日期:2023-04-14
通讯作者: 陈汉清,E-mail: chenhq921@163.com
作者简介:陈汉清,博士,华南理工大学附属第二医院(广州市第一人民医院),研究员,博士生导师。美国波士顿大学医学院和得州大学圣安东尼奥健康科学中心博士后,北京市海外引进高层次人才(青年项目),广州市青年后备人才,广州市医学骨干人才,国家自然科学基金评审专家。主要从事消化系统疾病发病机制及精准治疗研究。近5年共主持包括2项国自然等7项科研项目。共发表SCI 论文 40 余篇,其中,以第一作者/通讯作者在Hepatology、Nano Today、Small、Cancer Science等发表SCI论文21篇,其中IF>10有7篇。担任 Frontiers in Pharmacology、Frontiers in Endocrinology和Frontiers in Chemistry客座主编,Journal of Clinical and Translational Hepatology和《广州医药》编委,iMeta和Hepatobiliary & Pancreatic Diseases International青年编委。
基金资助:
国家自然科学基金青年科学项目(82000250);国家自然科学基金面上项目(32171370);广东省自然科学基金面上项目(2021A1515011005,2022A1515010415)

Research progress of genome editing for constructing the animal models of nonalcoholic fatty liver disease

LI Xinghui^1,2, GUO Chen^1,2, CHEN Hanqing^1,2

1 Center for Medical Research on Innovation and Translation, Guangzhou First People's Hospital, Guangzhou 510180, China
2 Department of Gastroenterology and Hepatology, the Second Affiliated Hospital, School of Medicine, South China University of Technology, Guangzhou 510180, China

Received:2022-12-10 Online:2023-03-20 Published:2023-04-14

摘要/Abstract

摘要： 非酒精性脂肪性肝病(NAFLD)是世界范围内慢性肝病的一个主要原因,约15%的NAFLD患者会发展为非酒精性脂肪性肝炎、肝纤维化、肝硬化甚至肝癌。目前其发病及进展机制尚未明确,也无有效治疗手段。因此,构建临床前NAFLD动物模型至关重要,有助于为NAFLD提供临床治疗的新方案。本文将系统分析目前已构建的NAFLD动物模型在临床前研究中的局限性,并重点总结和综述基于基因编辑在NAFLD动物模型构建中的应用及研究进展,这对于探讨NAFLD发病机制及新药研发具有重要的临床意义。

关键词: 非酒精性脂肪性肝病, 动物模型, 基因编辑

Abstract: Nonalcoholic fatty liver disease (NAFLD) is a leading cause of chronic liver disease worldwide, and about 15% of NAFLD patients will develop into nonalcoholic steatohepatitis, hepatic fibrosis, cirrhosis, and ultimately hepatocellular carcinoma. However, the biological mechanism of the pathogenesis and progression of NAFLD is not fully understood, and there are still no effective or targeted therapies for NAFLD. Therefore, it is an urgent need to construct pre-clinical animal models of NAFLD, which will help to better understand and explore the potential therapeutic strategy in the treatment of NAFLD. Here, we summarize the recent advances and limitations of the established animal models of NAFLD and focus on the potential application and research progress of genome editing for constructing the animal models of NAFLD. There animal models will be very useful to reveal the pathologic mechanism of human NAFLD, and to screen new therapeutic drugs.

Key words: nonalcoholic fatty liver disease, animal model, genome editing

李兴会, 郭晨, 陈汉清. 基因编辑在非酒精性脂肪性肝病动物模型构建中的应用及研究进展[J]. 广州医药, 2023, 54(3): 8-13.

LI Xinghui, GUO Chen, CHEN Hanqing. Research progress of genome editing for constructing the animal models of nonalcoholic fatty liver disease[J]. Guangzhou Medical Journal, 2023, 54(3): 8-13.

参考文献

[1] SHEKA A C, ADEYI O, THOMPSON J,et al.Nonalcoholic steatohepatitis: A review[J].JAMA,2020,323(12):1175-1183.
[2] FRIEDMAN S L, NEUSCHWANDER-TETRI B A, RINELLA M,et al. Mechanisms of NAFLD development and therapeutic strategies[J].Nat Med,2018,24(7):908-922.
[3] COTTER T G, RINELLA M.Nonalcoholic Fatty Liver Disease 2020: The State of the Disease[J].Gastroenterology,2020,158(7):1851-1864.
[4] TAN D J H, NG C H, LIN S Y, et al. Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis[J].Lancet Oncol,2022, 23(4):521-530.
[5] ZHOU J, BAI L, ZHANG X J, et al. Nonalcoholic fatty liver disease and cardiac remodeling risk: Pathophysiological mechanisms and clinical implications[J].Hepatology,2021,74(5):2839-2847.
[6] ADAMS L A, ANSTEE Q M, TILG H, et al. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases[J].Gut, 2017,66(6):1138-1153.
[7] TARGHER G, BYRNE C D, TILG H.NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications[J].Gut,2020,69(9):1691-1705.
[8] LOOMBA R, FRIEDMAN S L, SHULMAN G I.Mechanisms and disease consequences of nonalcoholic fatty liver disease[J].Cell,2021,184(10):2537-2564.
[9] TACKE F, WEISKIRCHEN R.Non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH)-related liver fibrosis: mechanisms, treatment and prevention[J].Ann Transl Med,2021,9(8):729.
[10] TSUCHIDA T, LEE Y A, FUJIWARA N,et al. A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer[J].J Hepatol,2018,69(2):385-395.
[11] ASGHARPOUR A, CAZANAVE S C, PACANA T, et al.A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer[J].J Hepatol,2016, 65(3):579-588.
[12] COLE B K, FEAVER R E, WAMHOFF B R, et al. Non-alcoholic fatty liver disease (NAFLD) models in drug discovery[J].Expert Opin Drug Discov,2018,13(2):193-205.
[13] SANTHEKADUR P K, KUMAR D P, SANYAL A J.Preclinical models of non-alcoholic fatty liver disease[J].J Hepatol,2018,68(2):230-237.
[14] FAN J G, CAO H X.Role of diet and nutritional management in non-alcoholic fatty liver disease[J].J Gastroenterol Hepatol,2013,28(Suppl 4):81-87.
[15] RINELLA M E, ELIAS M S, SMOLAK R R, et al. Mechanisms of hepatic steatosis in mice fed a lipogenic methionine choline-deficient diet[J].J Lipid Res,2008, 49(5):1068-1076.
[16] WELTMAN M D, FARRELL G C, LIDDLE C.Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation[J].Gastroenterology, 1996,111(6):1645-1653.
[17] FUJII M, SHIBAZAKI Y, WAKAMATSU K,et al. A murine model for non-alcoholic steatohepatitis showing evidence of association between diabetes and hepatocellular carcinoma[J].Med Mol Morphol,2013,46(3):141-152.
[18] LI X, WU Y, ZHAO J, et al. Distinct cardiac energy metabolism and oxidative stress adaptations between obese and non-obese type 2 diabetes mellitus[J].Theranostics, 2020,10(6):2675-2695.
[19] MINAMI Y, YUAN Y, UEDA H R.High-throughput genetically modified animal experiments achieved by next-generation mammalian genetics[J].J Biol Rhythms,2022, 37(2):135-151.
[20] ZHANG Y, CHUA S Jr.Leptin function and regulation[J].Compr Physiol,2017,8(1):351-369.
[21] GO G W, MANI A.Low-density lipoprotein receptor (LDLR) family orchestrates cholesterol homeostasis[J].Yale J Biol Med,2012,85(1):19-28.
[22] SUBRAMANIAN S, GOODSPEED L, WANG S, et al. Dietary cholesterol exacerbates hepatic steatosis and inflammation in obese LDL receptor-deficient mice[J].J Lipid Res,2011,52(9):1626-1635.
[23] HUEBBE P, RIMBACH G.Evolution of human apolipoprotein E (APOE) isoforms: Gene structure, protein function and interaction with dietary factors[J].Ageing Res Rev,2017(37):146-161.
[24] VÉNIANT M M, WITHYCOMBE S, YOUNG S G.Lipoprotein size and atherosclerosis susceptibility in Apoe(-/-) and Ldlr(-/-) mice[J].Arterioscler Thromb Vasc Biol, 2001,21(10):1567-1570.
[25] ITOH M, SUGANAMI T, NAKAGAWA N, et al.Melanocortin 4 receptor-deficient mice as a novel mouse model of nonalcoholic steatohepatitis[J].Am J Pathol,2011, 179(5):2454-2463.
[26] HAINER V, ALDHOON HAINEROVÁ I, KUNEŠOVÁ M, et al. Melanocortin pathways: suppressed and stimulated melanocortin-4 receptor (MC4R)[J].Physiol Res,2020,69(Suppl 2):S245-S254.
[27] CHEN C Y, CHEN J, HE L, et al. PTEN: Tumor Suppressor and Metabolic Regulator[J].Front Endocrinol (Lausanne),2018(9):338.
[28] HORIE Y, SUZUKI A, KATAOKA E, et al. Hepatocyte-specific PTEN deficiency results in steatohepatitis and hepatocellular carcinomas[J].J Clin Invest,2004, 113(12):1774-1783.
[29] GANDHI C R, CHAILLET J R, NALESNIK M A, et al. Liver-specific deletion of augmenter of liver regeneration accelerates development of steatohepatitis and hepatocellular carcinoma in mice[J].Gastroenterology,2015,148(2):379-391.e4.
[30] JIANG S, MINTER L C, STRATTON S A, et al. TRIM24 suppresses development of spontaneous hepatic lipid accumulation and hepatocellular carcinoma in mice[J].J Hepatol,2015,62(2):371-379.
[31] EBERLÉ D, HEGARTY B, BOSSARD P, et al. SREBP transcription factors: master regulators of lipid homeostasis[J].Biochimie,2004,86(11):839-848.
[32] NAKAYAMA H, OTABE S, UENO T, et al. Transgenic mice expressing nuclear sterol regulatory element-binding protein 1c in adipose tissue exhibit liver histology similar to nonalcoholic steatohepatitis[J].Metabolism,2007,56(4):470-475.
[33] NAKAGAWA H, UMEMURA A, TANIGUCHI K, et al. ER stress cooperates with hypernutrition to trigger TNF-dependent spontaneous HCC development[J].Cancer Cell,2014,26(3):331-343.
[34] ARSOV T, LARTER C Z, NOLAN C J, et al. Adaptive failure to high-fat diet characterizes steatohepatitis in Alms1 mutant mice[J].Biochem Biophys Res Commun,2006,342(4):1152-1159.

基因编辑在非酒精性脂肪性肝病动物模型构建中的应用及研究进展

Research progress of genome editing for constructing the animal models of nonalcoholic fatty liver disease

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 3

编辑推荐

Metrics

本文评价

[1]	吴勇, 况钦, 周梦瑶, 杜彬, 毋楠, 冯涛. SNHG12在乙肝病毒X蛋白诱导肝癌发生中的作用研究[J]. 广州医药, 2023, 54(1): 16-24.
[2]	吴洁莹, 孙逊沙, 李发涛, 陈劲松, 谢闺娥, 李焱, 吴韶清. 建立靶向CXCR7基因的CRISPR/Cas9 基因编辑系统及其应用[J]. 广州医药, 2020, 51(5): 16-20.
[3]	曹创裕, 周永健, 李瑜元. 非酒精性脂肪性肝病进展相关基因的生物信息学分析[J]. 广州医药, 2018, 49(6): 24-29.